All In Biotech

Drug Trial Radar · NCT06357377

A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors

An Open Label, Phase 1b Safety, Dose-finding, Brain Tumor Delivery, and Pharmacokinetics Study of Intranasal NEO100 in Patients With Pediatric-type Select Brain Tumors

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Sep 8, 2026

Primary completion

Jun 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Neonc Technologies, Inc.Industry
Sponsor type
Industry
First posted
Apr 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, Phase 1b safety, dose-finding, brain tumor delivery, and pharmacokinetics study of intranasal NEO100 in patients with pediatric-type diffuse high grade gliomas. Patients will receive IN NEO100 that will follow a dose titration design, followed by a standard dose escalation design to establish safety. Brain tumor delivery of NEO100 will be confirmed in each disease sub-type by surgical resection/needle biopsy only if clinically indicated and scheduled for clinical purposes and testing with residual tissue for NEO100 and the major metabolite of NEO100 (Perillic Acid).

Conditions

  • Pediatric Tumor of CNS
  • Pediatric Tumor of Brain
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • Pediatric Tumor of Brain Stem
  • Pineocytoma
  • Choroid Plexus Carcinoma, Childhood
  • Spinal Cord Tumor
  • High Grade Glioma

Interventions

  • NEO100Drug

    NEO100 is a purified form (\>98.5%) of the naturally occurring monoterpene perillyl alcohol. NEO100 drug product is a non-sterile solution for intranasal administration. It is compounded as a 10% solution in a 50:50 mixture of ethanol:glycerol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Nature and severity of adverse eventsTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital Orange County (CHOC)

    Orange, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.